- Home
- PETZ vs XAIR Comparison
PETZ vs XAIR Comparison
Compare PETZ & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | XAIR |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 10.5M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | PETZ | XAIR |
|---|---|---|
| Price | $1.11 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 15.5K | ★ 22.5M |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | $1,046,006.00 | ★ $5,802,000.00 |
| Revenue This Year | N/A | $127.85 |
| Revenue Next Year | N/A | $179.78 |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $0.65 | $0.67 |
| 52 Week High | $1.68 | $10.40 |
Technical Indicators
Market Signals| Indicator | PETZ | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 69.39 | 46.38 |
| Support Level | $1.04 | $1.43 |
| Resistance Level | $1.20 | $2.26 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 98.24 | 20.53 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.